VRX up +0.87% percent Today $VRX High is at 133.21 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 14, 2014 at 11:47 AM

VRX up +0.87% percent Today $VRX High is at 133.21 and the Low 131.34 with current volume of 539,926.

Recent News posted below.

Valeant Pharmaceuticals International VRX other info.
http://investorshangout.com/Valeant-Pharmaceu...VRX-53038/

VRX Valeant Pharmaceuticals International Recent Headline News

Valeant Should Drop Allergan Bid And Go For Zoetis
Kanak Kanti De - at Seeking Alpha - Fri Nov 14, 7:30AM CST

ZTS: 43.07 (-0.17), AGN: 197.17 (+0.96), VRX: 133.21 (+1.31), ACT: 243.26 (+1.63)

Will Actavis Snatch Allergan, Valeant Settle for Zoetis? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:28PM CST
A report from Bloomberg stated that Actavis is in discussions to Allergan for a deal worth at least $60 billion.
ZTS: 43.07 (-0.17), AGN: 197.17 (+0.96), ACT: 243.26 (+1.63), VRX: 133.21 (+1.31)

Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey
CNW Group - Thu Nov 13, 4:00PM CST
Expansion of its U.S. headquarters solidifies commitment to grow jobs and support the local economy
VRX: 133.21 (+1.31), VRX.TO: 150.54 (+0.39)

Allergan buyout said nearing
at Investor's Business Daily - Wed Nov 12, 5:51PM CST
Drugmaker Actavis (ACT) is reportedly near a deal to take over Botox maker Allergan (AGN) for at least $60 bil. An agreement could be reached in a matter of weeks, said Bloomberg sources. But in order to avoid a looming hostile takeover bid from...
AGN: 197.17 (+0.96), VRX: 133.21 (+1.31), ACT: 243.26 (+1.63)

Actavis, Allergan Reported Near Deal As Valeant Lurks
at Investor's Business Daily - Wed Nov 12, 11:43AM CST
The drug-industry rumor mill got a fresh surge of energy Wednesday on a report that emerging drug giant Actavis (ACT) is nearing a deal to buy Botox maker Allergan (AGN) for at least $60 billion. Reports that the two companies were talking have been...
ZTS: 43.07 (-0.17), AGN: 197.17 (+0.96), VRX: 133.21 (+1.31), ACT: 243.26 (+1.63)

Cramer Says Zoetis Could Be Next M&A Target for Ackman, Valeant
at The Street - Wed Nov 12, 10:37AM CST
Bill Ackman has a stake in Valeant Pharmaceuticals, as well as Zoetis, the latter of which may become a takeover target by the former, Jim Cramer says.
ZTS: 43.07 (-0.17), VRX: 133.21 (+1.31)

Today's Market: Mergers, Rumors And Earnings Moving These Stocks
Matthew Smith - at Seeking Alpha - Wed Nov 12, 10:04AM CST

ZTS: 43.08 (-0.16), T: 35.81 (+0.20), VRX: 133.21 (+1.31), FOSL: 106.87 (-2.94), BBT: 37.67 (+0.09), PFE: 30.30 (-0.12), KORS: 71.57 (+0.83), SUSQ: 13.14 (+0.08)

Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 43.08 (-0.16), AGN: 197.17 (+0.96), HLF: 37.53 (-0.32), VRX: 133.21 (+1.31), PFE: 30.30 (-0.12), MRK: 58.96 (-0.58), LLY: 67.48 (-0.20)

Allergan tweaks bylaws pertaining to special meeting requests
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:07AM CST

AGN: 197.17 (+0.96), VRX: 133.21 (+1.31)

Wall Street Breakfast: Global Banks Fined $3.4B In Forex Probe
Wall Street Breakfast - Seeking Alpha - Wed Nov 12, 5:30AM CST
Economy Japanese stocks scaled seven-year highs this morning on further speculation that Prime Minister Shinzo Abe will postpone a planned sales tax hike and call a general election for December. The Sankei newspaper reported that Abe would...
VRX: 133.21 (+1.31), MDT: 69.07 (-0.31), C: 53.40 (-0.04), WMT: 82.43 (-0.51), RBS: 11.78 (+0.03), UBS: 17.52 (-0.02), NOK: 7.82 (-0.44), YHOO: 51.06 (+0.56), PBR: 9.64 (-0.56), SPY: 204.20 (+0.01), SAP: 66.52 (-0.11), EBAY: 54.38 (+0.01), JPM: 60.50 (+0.27), BHP: 57.78 (+0.15), AAPL: 113.95 (+1.13), BCS: 14.55 (+0.12), FRM: 6.23 (-0.03), COV: 93.85 (+0.18), HSBC: 50.21 (+0.06), FRGI: 56.74 (+0.31), ZTS: 43.08 (-0.16), DLA: 10.45 (-0.10), QQQ: 103.09 (+0.19), AOL: 46.53 (+0.16), BABA: 114.78 (-0.06)

Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 5:18PM CST
Irvine, Calif.-based Botox maker Allergan is desperately trying to fend off a takeover bid from Valeant Pharmaceuticals , a company with a history of buying rivals and slashing their work forces. In an interesting twist, this deal is being...
AGN: 197.17 (+0.96), VRX: 133.21 (+1.31), ACT: 243.26 (+1.63)

Zoetis could be fallback option for Valeant
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:16PM CST

AGN: 197.17 (+0.96), ZTS: 43.08 (-0.16), ACT: 243.26 (+1.63), VRX: 133.21 (+1.31)

Zoetis jumps 6% on report of Ackman stake
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 2:48PM CST

ZTS: 43.08 (-0.16), VRX: 133.21 (+1.31)

Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.76 (+0.01), AGN: 197.17 (+0.96), ACT: 243.26 (+1.63), VRX: 133.21 (+1.31), MDT: 69.07 (-0.31), SLXP: 99.53 (+2.54), SNY: 46.42 (-0.11)

Big Cap 20 Stuffed With Medical Names
at Investor's Business Daily - Mon Nov 10, 6:34PM CST
Nine of the Big Cap 20 names this week are in medical-related fields, revealing that the leadership among these names over the past few years has continued despite October's correction, which whittled more than 10% off the Nasdaq. Alexion...
ABC: 89.18 (+0.10), VRX: 133.21 (+1.31), ALXN: 189.17 (-4.42), AMGN: 158.43 (-2.42), MYL: 53.86 (-0.87), ILMN: 180.14 (-4.86), CELG: 103.74 (-3.69)

Salix Crashes on Inventory Issues, Lowered Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 1:56PM CST
Salix's (SLXP) wholesale inventory levels for its products were much higher than previously announced.
AGN: 197.17 (+0.96), VRX: 133.21 (+1.31), AUXL: 32.25 (-0.10), SLXP: 99.53 (+2.54)

Valeant Pharmaceuticals Sends Letter To Physician Customers
CNW Group - Fri Nov 07, 4:00PM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today sent a letter to physician customers in order to address misconceptions and clarify how Valeant operates its business.
VRX: 133.21 (+1.31), VRX.TO: 150.54 (+0.39)

Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 197.17 (+0.96), VRX: 133.21 (+1.31), DVA: 77.34 (+0.30), GILD: 102.26 (-1.94), SLXP: 99.53 (+2.54), ICPT: 159.07 (+0.21), HUM: 137.35 (-1.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

VetsinTech's AI Training Boosts Military Careers

A New Spin on Engineering Careers Sometimes it feels like every corner I turn in this market maze, there’s something about AI. It’s not just chirping in the tech world anymore; it’s banging on the doors of sectors like engineering, aerospace, and manufacturing. And now, VetsinTech is tossing its hat into the AI ring with a fresh program aimed at blending military...

Montessori and Tech: A New Era of Integration

Reimagining Montessori with Technology Let's take a stroll down the road less traveled—the intersection of Montessori education and tech. For over a century, Montessori schools have valued individual child development, autonomy, and a purpose-driven environment. But let's face it, their technology hasn't always had the same handcrafted finesse. That's where illumine...

Home Buying: Unmasking All the Real Budget Costs

Home Buying: More Costs Than Meets the Eye Let's face it, buying a home is no stroll in the park. It's a tangled web of numbers and surprises that can leave even the savviest buyer in a daze. Thank goodness for articles like the one from HelloNation featuring Serena LoPiccolo-Smith, which make the invisible visible when it comes to the financial intricacies of home...

Franco-Nevada's Q3 Results Loom: Investors Ready

Gearing Up: Franco-Nevada's Q3 Numbers on the Horizon You know the drill! Franco-Nevada's third quarter results won't just trickle in—they'll set the tone for the months ahead. Mark your calendar: November 11th after the market closes is the magic hour when you'll get the skinny on their Q3 performance. The next morning, bright and early at 8:00 AM ET, they'll hash it...

Think Tank Pushes for Bold Parkinson's Prevention Plan

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...

Paradigm Therapeutics: A Beacon in Rare Diseases

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

New Data on SKYRIZI Offers Hope for Crohn's Patients

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Omneky Outshines Competitors in AI Ad Scoring

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Honeywell Aerospace Faces Legal Turbulence in Fraud Case

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

Laars Welcomes Women in Manufacturing to Facility Tour

Opening Doors and Minds in Manufacturing On October 15, Laars Heating Systems throws wide open its Rochester, N.H., facility to a group that's rewriting the rulebook: women in manufacturing. It's not just another day in the life of assembly lines and engineering desks, folks. This is about giving a platform to those often sidelined in the field of boilers and water...